|
1
|
Smallridge RC, Marlow LA and Copland JA:
Anaplastic thyroid cancer: molecular pathogenesis and emerging
therapies. Endocr Relat Cancer. 16:17–44. 2009. View Article : Google Scholar
|
|
2
|
He H, Jazdzewski K, Li W, Liyanarachchi S,
Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al:
The role of microRNA genes in papillary thyroid carcinoma. Proc
Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pallante P, Visone R, Ferracin M, Ferraro
A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M,
Negrini M, et al: MicroRNA deregulation in human thyroid papillary
carcinomas. Endocr Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nikiforova MN, Tseng GC, Steward D, Diorio
D and Nikiforov YE: MicroRNA expression profiling of thyroid
tumors: biological significance and diagnostic utility. J Clin
Endocrinol Metab. 93:1600–1608. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aherne ST, Smyth PC, Flavin RJ, Russell
SM, Denning KM, Li JH, Guenther SM, O'Leary JJ and Sheils OM:
Geographical mapping of a multifocal thyroid tumour using genetic
alteration analysis and miRNA profiling. Mol Cancer. 7:892008.
View Article : Google Scholar
|
|
6
|
Kim HJ, Kim YH, Lee DS, Chung J-K and Kim
S: In vivo imaging of functional targeting of miR-221 in papillary
thyroid carcinoma. J Nucl Med. 49:1686–1693. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mitomo S, Maesawa C, Ogasawara S, Iwaya T,
Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu
N, et al: Downregulation of miR-138 is associated with
overexpression of human telomerase reverse transcriptase protein in
human anaplastic thyroid carcinoma cell lines. Cancer Sci.
99:280–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Keutgen XM, Filicori F, Crowley MJ, Wang
Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA,
Zarnegar R, et al: A panel of four miRNAs accurately differentiates
malignant from benign indeterminate thyroid lesions on fine needle
aspiration. Clin Cancer Res. 18:2032–2038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chou CK, Yang KD, Chou FF, Huang CC, Lan
YW, Lee YF, Kang HY and Liu RT: Prognostic implications of miR-146b
expression and its functional role in papillary thyroid carcinoma.
J Clin Endocrinol Metab. 98:E196–E205. 2013. View Article : Google Scholar
|
|
10
|
Visone R, Russo L, Pallante P, De Martino
I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM and
Fusco A: MicroRNAs (miR)-221 and miR-222, both overexpressed in
human thyroid papillary carcinomas, regulate p27Kip1
protein levels and cell cycle. Endocr Relat Cancer. 14:791–798.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petrocca F, Vecchione A and Croce CM:
Emerging role of miR-106b-25/miR-17-92 clusters in the control of
transforming growth factor beta signaling. Cancer Res.
68:8191–8194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim Y-K, Yu J, Han TS, Park SY, Namkoong
B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK and Kim VN: Functional
links between clustered microRNAs: Suppression of cell-cycle
inhibitors by microRNA clusters in gastric cancer. Nucleic Acids
Res. 37:1672–1681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang
Z, Tan F, Tan X, Zhou F, Sun J, et al: MicroRNA-25 promotes cell
migration and invasion in esophageal squamous cell carcinoma.
Biochem Biophys Res Commun. 421:640–645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Zuo Z, Lu X, Wang L, Wang H and
Zhu Z: MiR-25 regulates apoptosis by targeting Bim in human ovarian
cancer. Oncol Rep. 27:594–598. 2012.
|
|
15
|
Kan T, Sato F, Ito T, Matsumura N, David
S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, et al: The
miR-106b-25 polycistron, activated by genomic amplification,
functions as an oncogene by suppressing p21 and Bim.
Gastroenterology. 136:1689–1700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Visone R, Pallante P, Vecchione A,
Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V,
Borbone E, et al: Specific microRNAs are downregulated in human
thyroid anaplastic carcinomas. Oncogene. 26:7590–7595. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Esposito F, Tornincasa M, Pallante P,
Federico A, Borbone E, Pierantoni GM and Fusco A: Down-regulation
of the miR-25 and miR-30d contributes to the development of
anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J
Clin Endocrinol Metab. 97:E710–E718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brennecke J, Stark A, Russell RB and Cohen
SM: Principles of microRNA-target recognition. PLoS Biol.
3:e852005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu YH, Kuo HK and Chang KW: The evolving
transcriptome of head and neck squamous cell carcinoma: a
systematic review. PLoS One. 3:e32152008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kurokawa A, Nagata M, Kitamura N, Noman
AA, Ohnishi M, Ohyama T, Kobayashi T, Shingaki S and Takagi R;
Oral, Maxillofacial Pathology, and Surgery Group: Diagnostic value
of integrin alpha3, beta4, and beta5 gene expression levels for the
clinical outcome of tongue squamous cell carcinoma. Cancer.
112:1272–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cariati M, Naderi A, Brown JP, Smalley MJ,
Pinder SE, Caldas C and Purushotham AD: Alpha-6 integrin is
necessary for the tumourigenicity of a stem cell-like subpopulation
within the MCF7 breast cancer cell line. Int J Cancer. 122:298–304.
2008. View Article : Google Scholar
|
|
27
|
Gerson KD, Maddula VSRK, Seligmann BE,
Shearstone JR, Khan A and Mercurio AM: Effects of β4 integrin
expression on microRNA patterns in breast cancer. Biol Open.
1:658–666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cuenda A: Mitogen-activated protein kinase
kinase 4 (MKK4). Int J Biochem Cell Biol. 32:581–587. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fagin JA and Mitsiades N: Molecular
pathology of thyroid cancer: diagnostic and clinical implications.
Best Pract Res Clin Endocrinol Metab. 22:955–969. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang L, Pan Y and Dai JL: Evidence of MKK4
pro-oncogenic activity in breast and pancreatic tumors. Oncogene.
23:5978–5985. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xin W, Yun KJ, Ricci F, Zahurak M, Qiu W,
Su GH, Yeo CJ, Hruban RH, Kern SE and Iacobuzio-Donahue CA:
MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of
immunohistochemistry and relationship to disease course. Clin
Cancer Res. 10:8516–8520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chiariello M, Visconti R, Carlomagno F,
Melillo RM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA,
Gutkind JS, et al: Signalling of the Ret receptor tyrosine kinase
through the c-Jun NH2-terminal protein kinases (JNKS): evidence for
a divergence of the ERKs and JNKs pathways induced by Ret.
Oncogene. 16:2435–2445. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mahalingam D, Szegezdi E, Keane M, de Jong
S and Samali A: TRAIL receptor signalling and modulation: are we on
the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ashkenazi A and Dixit VM: Apoptosis
control by death and decoy receptors. Curr Opin Cell Biol.
11:255–260. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mitsiades N, Poulaki V, Tseleni-Balafouta
S, Koutras DA and Stamenkovic I: Thyroid carcinoma cells are
resistant to FAS-mediated apoptosis but sensitive to tumor necrosis
factor-related apoptosis-inducing ligand. Cancer Res. 60:4122–4129.
2000.PubMed/NCBI
|
|
36
|
Ohtsuka T, Buchsbaum D, Oliver P, Makhija
S, Kimberly R and Zhou T: Synergistic induction of tumor cell
apoptosis by death receptor antibody and chemotherapy agent through
JNK/p38 and mitochondrial death pathway. Oncogene. 22:2034–2044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Söderström TS, Poukkula M, Holmström TH,
Heiskanen KM and Eriksson JE: Mitogen-activated protein
kinase/extracellular signal-regulated kinase signaling in activated
T cells abrogates TRAIL-induced apoptosis upstream of the
mitochondrial amplification loop and caspase-8. J Immunol.
169:2851–2860. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Razumilava N, Bronk SF, Smoot RL, Fingas
CD, Werneburg NW, Roberts LR and Mott JL: miR-25 targets
TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and
promotes apoptosis resistance in cholangiocarcinoma. Hepatology.
55:465–475. 2012. View Article : Google Scholar
|
|
39
|
Newsom-Davis T, Prieske S and Walczak H:
Is TRAIL the holy grail of cancer therapy? Apoptosis. 14:607–623.
2009. View Article : Google Scholar : PubMed/NCBI
|
